Stocktoria
Sun Pharmaceutical Industries Limited SUNPHARMA.NS
IN · National Stock Exchange of India · XNSE · stock · Healthcare · website
Sun Pharmaceutical Industries Limited financials (annual, from 10-K)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | $582.2B | $520.4B | $477.6B | $432.8B |
| Gross profit | $466.8B | $412.9B | $356.9B | $313.4B |
| SG&A expense | — | $103.0B | $92.2B | $80.4B |
| Operating income | $135.5B | $125.1B | $104.7B | $92.8B |
| Interest expense | $3.4B | $2.3B | $2.4B | $1.7B |
| Income tax | $35.5B | $27.7B | $14.4B | $8.5B |
| Net income | $114.8B | $109.3B | $95.8B | $84.7B |
| EPS (diluted) | $47.80 | $45.60 | $39.90 | $35.30 |
| Operating cash flow | $124.2B | $140.7B | $121.3B | $49.6B |
| Free cash flow | $88.1B | $119.4B | $99.3B | $28.7B |
| Cash & equivalents | $97.7B | $102.7B | $92.9B | $46.2B |
| Inventory | $114.9B | $102.4B | $98.7B | $105.1B |
| Total assets | $1.09T | $921.0B | $855.0B | $807.4B |
| Total liabilities | $249.1B | $196.1B | $183.7B | $214.3B |
| Shareholders' equity | $835.7B | $722.2B | $636.7B | $560.0B |
Growth · year-over-year · Revenue CAGR 10.4%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +11.9% | +9.0% | +10.4% | — |
| Net income growth | +5.0% | +14.1% | +13.0% | — |
| EPS growth | +4.8% | +14.3% | +13.0% | — |
| Free cash flow growth | -26.2% | +20.2% | +245.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · IN · as of 2026-03-31. Figures in INR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.